Resource Summary Report

Generated by kravitz2 on Jul 31, 2026

ADTEx

RRID:SCR_012059
Type: Tool

Proper Citation

ADTEx (RRID:SCR_012059)

Resource Information

URL: http://sourceforge.net/projects/adtex/

Proper Citation: ADTEx (RRID:SCR_012059)

Description: A software tool for copy number variation (CNV) detection for whole-exome data from paired tumour/matched normal samples.

Resource Type: software resource

Defining Citation: PMID:23368785

Keywords: standalone software, python, r

Availability: GNU General Public License

Resource Name: ADTEx

Resource ID: SCR_012059

Alternate IDs: OMICS_03365

Record Creation Time: 20220129T080308+0000

Record Last Update: 20260725T190730+0000

Ratings and Alerts

No rating or validation information has been found for ADTEx.

No alerts have been found for ADTEx.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 90 mentions in open access literature.

Listed below are recent publications. The full list is available at kravitz2 .

Zhu J, et al. (2025) Genomic profiles and prognostic biomarkers of resectable lung adenocarcinoma with a micropapillary component. Frontiers in oncology, 15, 1574817.

Lei Y, et al. (2025) Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy. Annals of medicine, 57(1), 2581815.

Gao Y, et al. (2025) High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. Blood cancer discovery, 6(3), 191.

Liu H, et al. (2025) Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib. Cancer medicine, 14(21), e71319.

Wang Z, et al. (2025) Role of telomere maintenance genes as a predictive biomarker for colorectal cancer immunotherapy response and prognosis. Biomolecules & biomedicine, 25(12), 2696.

Zhang L, et al. (2025) High-grade uterine endometrial stromal sarcoma harboring GLI1 and MDM2/CDK4 co-amplifications. Diagnostic pathology, 20(1), 125.

Sun M, et al. (2025) Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features. Histopathology, 87(6), 904.

Yang L, et al. (2025) Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study. BMC cancer, 25(1), 1163.

Wu L, et al. (2025) Integration of Circulating Tumor DNA and Metabolic Parameters on 18F-Fludeoxyglucose Positron Emission Tomography for Outcome Prediction in Unresectable Locally Advanced Non-Small Cell Lung Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(13), e2413125.

Hu J, et al. (2025) MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer. Molecular oncology, 19(9), 2715.

Zhang H, et al. (2025) Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass. Annals of hematology, 104(6), 3359.

Jiang M, et al. (2024) Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response. Heliyon, 10(18), e37884.

Ding X, et al. (2024) Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. Cell communication and signaling : CCS, 22(1), 45.

Chen C, et al. (2024) Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA. Journal of cellular and molecular medicine, 28(14), e18576.

Zhang Y, et al. (2024) Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL). Cell reports. Medicine, 5(12), 101833.

Yang L, et al. (2024) Identification of novel diagnostic biomarkers associated with liver metastasis in colon adenocarcinoma by machine learning. Discover oncology, 15(1), 542.

Zhao Z, et al. (2023) Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Cancer medicine, 12(10), 11672.

Liu X, et al. (2023) Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases. Frontiers in oncology, 13, 1322635.

Lv L, et al. (2023) Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis. Clinical and experimental medicine, 23(6), 2675.

Tu HY, et al. (2023) Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy. Molecular oncology, 17(8), 1581.